Mirabegron And Ureteral Stent-related Pain (MAP) Trial

Condition:   Nephrolithiasis Interventions:   Drug: Mirabegron 50 MG;   Drug: Placebo oral tablet Sponsors:   St. Michael's Hospital, Toronto;   Canadian Urological Association Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials